PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $27.88 million. The enterprise value is $40.88 million.
| Market Cap | 27.88M |
| Enterprise Value | 40.88M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 6.99 million shares outstanding. The number of shares has decreased by -18.99% in one year.
| Current Share Class | 6.99M |
| Shares Outstanding | 6.99M |
| Shares Change (YoY) | -18.99% |
| Shares Change (QoQ) | +296.60% |
| Owned by Insiders (%) | 22.80% |
| Owned by Institutions (%) | 7.71% |
| Float | 4.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 248.96 |
| Forward PS | 89.95 |
| PB Ratio | 0.80 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 365.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.88.
| Current Ratio | 1.19 |
| Quick Ratio | 1.00 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,405.42 |
Financial Efficiency
Return on equity (ROE) is -64.78% and return on invested capital (ROIC) is -43.29%.
| Return on Equity (ROE) | -64.78% |
| Return on Assets (ROA) | -39.69% |
| Return on Invested Capital (ROIC) | -43.29% |
| Return on Capital Employed (ROCE) | -73.92% |
| Weighted Average Cost of Capital (WACC) | 4.50% |
| Revenue Per Employee | $2,732 |
| Profits Per Employee | -$503,098 |
| Employee Count | 41 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 1.52 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.23% in the last 52 weeks. The beta is 0.54, so PAVmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -70.23% |
| 50-Day Moving Average | 4.91 |
| 200-Day Moving Average | 7.38 |
| Relative Strength Index (RSI) | 38.66 |
| Average Volume (20 Days) | 25,205 |
Short Selling Information
The latest short interest is 7,939, so 0.11% of the outstanding shares have been sold short.
| Short Interest | 7,939 |
| Short Previous Month | 22,659 |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.19% |
| Short Ratio (days to cover) | 0.18 |
Income Statement
In the last 12 months, PAVmed had revenue of $112,000 and -$20.63 million in losses. Loss per share was -$9.85.
| Revenue | 112,000 |
| Gross Profit | -247,000 |
| Operating Income | -26.70M |
| Pretax Income | -16.43M |
| Net Income | -20.63M |
| EBITDA | -26.62M |
| EBIT | -26.70M |
| Loss Per Share | -$9.85 |
Balance Sheet
The company has $4.07 million in cash and $17.07 million in debt, with a net cash position of -$13.00 million or -$1.86 per share.
| Cash & Cash Equivalents | 4.07M |
| Total Debt | 17.07M |
| Net Cash | -13.00M |
| Net Cash Per Share | -$1.86 |
| Equity (Book Value) | 19.31M |
| Book Value Per Share | 4.98 |
| Working Capital | 770,000 |
Cash Flow
In the last 12 months, operating cash flow was -$7.73 million and capital expenditures -$52,000, giving a free cash flow of -$7.78 million.
| Operating Cash Flow | -7.73M |
| Capital Expenditures | -52,000 |
| Depreciation & Amortization | 79,000 |
| Net Borrowing | 3.85M |
| Free Cash Flow | -7.78M |
| FCF Per Share | -$1.11 |
Margins
| Gross Margin | -220.54% |
| Operating Margin | -23,841.96% |
| Pretax Margin | -14,670.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 18.99% |
| Shareholder Yield | 18.99% |
| Earnings Yield | -73.98% |
| FCF Yield | -27.91% |
Analyst Forecast
The average price target for PAVmed is $36.50, which is 815.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $36.50 |
| Price Target Difference | 815.36% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 1,285.17% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
PAVmed has an Altman Z-Score of -10.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.8 |
| Piotroski F-Score | 2 |